Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Circulating Tumor Cells in Desmoid Tumors: New Perspectives

Full text
Author(s):
Braun, Alexcia C. [1] ; Campos, Fernando A. B. [2] ; Abdallah, Emne A. [1] ; Ruano, Anna P. C. [1] ; Medina, Tiago da S. [1] ; Tariki, Milena S. [2] ; Pinto, Fabio F. E. [3] ; de Mello, Celso A. L. [2] ; Chinen, Ludmilla T. D. [1]
Total Authors: 9
Affiliation:
[1] AC Camargo Canc Ctr, Int Ctr Res, Sao Paulo - Brazil
[2] AC Camargo Canc Ctr, Dept Clin Oncol, Sao Paulo - Brazil
[3] AC Camargo Canc Ctr, Dept Orthoped, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: FRONTIERS IN ONCOLOGY; v. 11, SEP 14 2021.
Web of Science Citations: 0
Abstract

Introduction Desmoid tumor (DT) is a rare neoplasm with high local recurrence rates, composed of fibroblastic cells that are characterized by the expression of key molecules, including the intermediate filament vimentin, cyclooxygenase-2 (COX-2), and nuclear beta-catenin, and lack of epithelial markers. Circulating tumor cells (CTCs) isolated from the peripheral blood of patients with sarcomas and other neoplasms can be used as early biomarkers of tumor invasion and dissemination. Moreover, CTCs can also re-colonize their tumors of origin through a process of ``tumor self-seeding.{''}</p> Objectives We aimed to identify CTCs in the peripheral blood of patients with DT and evaluate their expression of beta-catenin, transforming growth factor receptor I (TGF-beta RI), COX-2, and vimentin proteins.</p> Material and Methods We conducted a prospective study of patients with initial diagnosis or relapsed DT with measurable disease. Blood samples from each patient were processed and filtered by ISET(R) (Rarecells, France) for CTC isolation and quantification. The CTC expression of beta-catenin, COX-2, TGF-beta RI, and vimentin was analyzed by immunocytochemistry (ICC).</p> Results A total of 18 patients were included, and all had detectable CTCs. We found a concordance of beta-catenin expression in both CTCs and primary tumors in 42.8% (6/14) of cases by using ICC and immunohistochemistry, respectively.</p> Conclusions Our study identified a high prevalence of CTCs in DT patients. Concordance of beta-catenin expression between primary tumor and CTCs brings new perspectives to assess the dynamics of CTCs in the blood compartment, opening new avenues for studying the biology and behavior of DT. In addition, these results open the possibility of using CTCs to predict DT dynamics at the time of disease progression and treatment. Further studies with larger sample sizes are needed to validate our findings.</p> (AU)

FAPESP's process: 19/18100-8 - Analysis of blood markers in patients with Osteosarcoma, Soft Tissue Sarcomas and Desmoid Tumor
Grantee:Alexcia Camila Braun
Support Opportunities: Scholarships in Brazil - Doctorate